Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer
The authors assessed the relative contributions of BRAF and TERT promoter mutations to papillary thyroid cancer mortality. Papillary thyroid cancer–specific mortality occurred in as many as 22.7% of patients with the “genetic duet” of both mutations, vs 0.6% with neither mutation, 2.4% with the BRAF mutation alone, and 6.3% with the TERT promoter mutation alone. […]
